These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25324419)

  • 1. Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.
    Hesje CK; Drlica K; Blondeau JM
    J Antimicrob Chemother; 2015 Feb; 70(2):494-7. PubMed ID: 25324419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ; Chmelařová E
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
    Garrison MW; Nuemiller JJ
    Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries.
    Ko KS; Song JH; Lee MY; Park S; Kwon KT; Heo ST; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):337-41. PubMed ID: 16631337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
    Marco F; Dowzicky MJ
    J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
    Crandon JL; Banevicius MA; Nicolau DP
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1165-9. PubMed ID: 19114676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
    Biedenbach DJ; Beach ML; Jones RN
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
    Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Steckelberg JM
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative time-kill study of doxycycline, tigecycline, cefazolin and vancomycin against several clones of Staphylococcus aureus.
    Herrera M; Mobilia L; Posse G; Limansky A; Ballerini V; Bantar C
    Curr Clin Pharmacol; 2013 Nov; 8(4):332-9. PubMed ID: 23590512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.
    Kitzis MD; Ly A; Goldstein FW
    Antimicrob Agents Chemother; 2004 Jan; 48(1):366-7. PubMed ID: 14693571
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative Minimal Inhibitory and Mutant Prevention Concentration of Eight Antimicrobial Agents Against
    Yang F; Chen P; Wang H; Xing X; Wang S; Ishaq HM; Liao W
    Microb Drug Resist; 2022 Feb; 28(2):229-235. PubMed ID: 34851749
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus.
    Low DE; Kreiswirth BN; Weiss K; Willey BM
    Int J Antimicrob Agents; 2002 Sep; 20(3):220-2. PubMed ID: 12385702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.